Skip to content

Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections

Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections - A Retrospective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06185153
Acronym
CarbaVim
Enrollment
70
Registered
2023-12-29
Start date
2022-11-21
Completion date
2023-12-31
Last updated
2023-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carbapenemase-Producing Enterobacteriaceae

Keywords

Carbapenemase, Enterobacteriaceae, VIM-producing strains

Brief summary

Carbapenemase-producing Enterobacteriaceae (CPE) infections are emerging infections that pose a therapeutic challenge. These infections mainly occur in patients with prolonged hospitalization and repeated exposure to antibiotics. Certain strains, notably VIM-producing strains, may remain sensitive to carbapenems. CPE VIM strains are rare in France, but represent the main CPE strains in many countries. They are historically the main type of carbapenemases isolated at the Strasbourg University Hospital.

Detailed description

The circulation of multi-antibiotic-resistant bacterial strains is significant at the Strasbourg University Hospital and the investigators wish to report their local experience in the use of carbapenems in infections with enterobacteria producing carbapenemase type VIM.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient (≥18) * Treated at the HUS for a VIM-producing enterobacteria infection between 01/01/2011 and 11/30/2022 * Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes.

Exclusion criteria

* Patient having expressed his opposition to the retrospective reuse of his data for scientific research purposes.

Design outcomes

Primary

MeasureTime frame
Mortality at 28 daysMortality at 28 days after infection

Countries

France

Contacts

Primary ContactBaptiste HOELLINGER, MD
baptiste.hoellinger@chru-strasbourg.fr33 3 69 55 05 45

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026